My HPRA: Register

The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions.If you have any queries about the SPCs on our website then please e-mail vetinfo@hpra.ie


Eurican DAPPi lyophilisate and solvent for suspension for injection



Boehringer Ingelheim Vetmedica GmbHVPA10454/039/001

Main Information

Trade NameEurican DAPPi lyophilisate and solvent for suspension for injection
Active SubstancesAttenuated canine distemper virus, strain ba5
Attenuated canine adenovirus type 2, strain dk13
Attenuated canine parvovirus, strain cag2
Attenuated canine parainfluenza virus type 2, strain cgf 2004/75
Dosage FormLyophilisate and solvent for suspension for injection
Licence HolderBoehringer Ingelheim Vetmedica GmbH
License Holder AddressBinger Strasse 173
55216 Ingelheim am Rhein
Germany
Licence NumberVPA10454/039/001

Group Information

ATC CodeQI07AD04 canine distemper virus + canine adenovirus + canine parvovirus + canine parainfluenza virus
Therapeutic ClassImmunological - Live Vaccine
SpeciesDogs

Status

License statusAuthorised
Licence Issued22/07/2016
Legal StatusPOM: Prescription Only Medicine as defined in relevant national legislation

Documents

Summary of Product Characteristics *PDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
VariationsPDF Version

* The PDF document, together with the national-specific product information on this page, constitute the authorised SPC
« Back
Follow medicine

Print